CATEGORY: Press Release

BROOMFIELD, Colo. — Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the closing of a $10.4 million common-stock-only financing at $5.18 per share in a clean capital raise […]

Quarterly Nociscan scan volumes increased 114% year-over-year in Q4 2025 Annual Nociscan scan volumes increased 69% year-over-year in 2025 Debt-free balance sheet with $12.0 million in cash as of December 31, 2025, extending cash runway into 2027 and providing strategic flexibility for continued commercial growth Company aims to enroll approximately 25% of patients in CLARITY […]

Northwestern and Scripps Health join two previously announced sites in achieving this critical patient enrollment milestone Seven leading U.S. spine centers have now completed the regulatory and operational requirements to screen and enroll patients in CLARITY First readout on interim data expected after initial cohort of patients achieves 3-month follow up visit in 3Q 2026 […]

Featured article strengthens growing body of clinical evidence for Nociscan by highlighting a successful case study Special Pain issue features breakthrough innovations shaping the future of spine care IJSS publishes over 150 articles annually representing 40+ nations BROOMFIELD, Colo. — Aclarion, Inc ., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers […]

Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companies Strong track record of launching breakthrough technologies across spine, neurosurgery and pain management Strengthens Aclarion’s commercial execution as the Company expands adoption and payer engagement across the Eastern U.S. BROOMFIELD, Colo. — Aclarion, Inc ., (“Aclarion” or […]

Marks Aclarion’s first commercial sales hire with seasoned HealthTech leader and proven track record of advancing musculoskeletal imaging and spinal surgery Experiencing strong commercial traction in UK as first market worldwide with private insurers covering Nociscan Nociscan reimbursed by three of top four private insurers in UK, giving access to more than 5.2 million covered […]

Company previously announced it was selected as a finalist from more than 1,800 submissions Award win underscores growing impact of Aclarion’s breakthrough Nociscan solution for chronic low back pain BROOMFIELD, Colo. — Aclarion, Inc ., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help […]

Debt-free balance sheet with $13.3 million in cash as of today ($15.11 per share fully diluted) providing strategic flexibility for continued commercial growth Nociscan scan volumes increase +89% year-over-year with third consecutive quarter of record utilization across U.S., U.K., and E.U. markets CLARITY pivotal trial progressing on schedule and early 3-month readouts expected Q2 2026 […]

Panel discussion featured at the International Society of Pain and Neuroscience (ISPN) Annual Meeting in London titled United to Conquer Pain Session Co-Moderator Doug Beall, M.D. underscored that disc chemistry is the critical biomarker for diagnosing the leading cause of chronic low back pain Nociscan® combines MR Spectroscopy and proprietary AI algorithms to deliver data-driven insights […]

BROOMFIELD, Colo. — Aclarion, Inc ., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced its selection as a finalist in the Rising Star – Clinical Diagnostic Device category for the prestigious 2025 Digital Health Hub […]